Johnson & Johnson Stock (JNJ) News Today: FDA Approvals, Analyst Price Targets, and the 2026 Outlook (Dec. 18, 2025)
Johnson & Johnson shares traded near $208.42 on December 18, down 0.9% for the day. The U.S. FDA approved an expanded use for J&J MedTech’s TRUFILL n‑BCA system to treat chronic subdural hematoma. The stock remains weighed by ongoing talc litigation despite a strong year-to-date performance of nearly 50%.